Navigation Links
Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session

PLYMOUTH MEETING, Pa., June 25, 2007 /PRNewswire-FirstCall/ -- Genaera Corporation today announced that data from a preclinical study of trodusquemine (MSI-1436) for the treatment of obesity were presented during the American Diabetes Association (ADA) 67th Scientific Sessions, June 22-25 in Chicago, IL. Dr. Kristen Lantz, Genaera research scientist and lead author of Abstract #1801-P, presented, "Trodusquemine is a Multiple Pathway Inhibitor that Causes Differential Weight Loss, Reduces Adiposity, and Improves Plasma Insulin and Leptin Levels."

The poster presentation summarizes results from preclinical studies demonstrating that trodusquemine suppresses appetite and causes differential weight loss in a mouse model of diet-induced obesity (DIO). Data presented also indicates that trodusquemine selectively inhibits PTP-1B, an enzyme central to controlling the function of both the leptin and insulin pathways. In addition, trodusquemine was shown to reduce the size of adipocytes, reduce body fat with no reduction of lean mass, and improve glucose tolerance via inhibition of a unique combination of signaling pathways in the DIO mouse model, making trodusquemine a promising therapeutic candidate.

"This preclinical data supports our current Phase 1 clinical strategy for trodusquemine as a treatment for obesity and further reinforces our belief that trodusquemine may also be successful in the treatment of type 2 diabetes," stated Jack Armstrong, President and Chief Executive Officer of Genaera. "We believe that, if successful, trodusquemine could be an effective monotherapy able to treat both obesity and type 2 diabetes, and could revolutionize the way these metabolic diseases are treated."

Scientists from Genaera will be available for discussion of the poster today from 12:00 p.m. to 2:00 p.m. Central Time in the Poster Hall at the conference.

For more information online, please visit: '"/>




Page: 1 2 3 4

Related medicine technology :

1. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, ... OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE ... JURISDICTION AbbVie (NYSE: ABBV ) today announced financial ... "This was another very strong quarter for AbbVie, ... original guidance and announced plans to merge with Shire, a ...
(Date:7/25/2014)... N.Y. , July 25, 2014 /PRNewswire-iReach/ -- Dr. ... clinic, GPM Pediatrics, reacts to a recent study, which ... Photo - http://photos.prnewswire.com/prnh/20140723/129709 ... exposed to severe stress are more likely than others to ... months before pregnancy." There were two specific types ...
(Date:7/24/2014)... July 24, 2014  Parnell Pharmaceuticals Holdings Ltd ... will be added to Parnell,s already extensive pipeline ... Ltd, a biotechnology company. The compounds now known ... promise in bone regeneration and dermal regeneration, respectively. ... compounds for the veterinary market with the potential ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
(Date:7/25/2014)... IL (PRWEB) July 25, 2014 Progress ... ushered in a new era of promising brain tumor ... Harvard Medical School, director of the Center for Neuro-Oncology, ... Association (ABTA) annual Patient and Family Conference in Chicago, ... how science and new technology are impacting the development ...
(Date:7/25/2014)... According to the new report "Sapphire ... and Geography - Analysis & Forecast to 2013 - ... to reach $3.01 Billion by 2020 at a CAGR ... devices is expected to reach $6.17 billion by 2020 ... analysis of application and geography. , Browse more than ...
(Date:7/25/2014)... Jose, CA (PRWEB) July 25, 2014 ... MaaS360 WorkPlace Partner Program . Splashtop Business and Splashtop ... Market, and will leverage the MaaS360 WorkPlace SDK ... data. , Splashtop Business and Splashtop Enterprise offer secure ... any device. High performance, ease of use, ...
(Date:7/25/2014)... Agoura Hills dentist , Dr. Amir ... Zoom Whitening is one of the most powerful whitening treatments ... professional. This light-assisted treatment uses a prescription-strength gel that can ... to break up stains that are in both the enamel ... soft drink and tobacco stains. , About Dr. Amir ...
(Date:7/25/2014)... IL (PRWEB) July 25, 2014 Garth Brooks ... performance at the Allstate Arena in Rosemont. Garth Brooks was ... time he released his first single in 1989. Since "Much Too ... flocked to the shows from the Tulsa, Okl. native and in ... wanted to see him back on a stage and in the ...
Breaking Medicine News(10 mins):Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 2Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 6Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 2Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 3Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 4Health News:Agoura Hills Dentist, Dr. Amir Choroomi, is Now Offering a Promotion on Zoom Whitening 2Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 2Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 3
... Artery-opening procedure can be done up to 21 hours later ... (HealthDay News) -- Many people who arrive at hospital emergency ... hours for artery-opening angioplasty, even if an electrocardiogram (EKG) shows ... , There was no significant difference in key measures of ...
... , , CARDIFF, Calif., Sept. 1 ... ( http://www.jedimindinc.com ) announced today that their Medical ... for patients in wheelchairs. An estimated 1.6 million Americans residing ... National Health Interview Survey on Disability (NHIS-D). Jedi Mind,s Medical ...
... , , ATLANTA, Sept. 1 ... 50 schools across the U.S. with $2,000 ... ING Run For Something Better School Awards Program, financial ... for Sport and Physical Education (NASPE), is helping to ...
... Less invasive procedure shaves off lesions, researchers say , ... the esophagus can be treated effectively by less invasive, ... This is good news, as esophageal cancer arising from ... other cancer in the United States, and 90 percent ...
... Angeles, London, New Delhi, Singapore and Washington DC (1 ... and professional publisher is delighted to announce a new ... their official journal, Cephalalgia . Now in ... forum for original research papers, review articles and short ...
... available in French . , Montreal, ... autoimmune disorders which cause muscular inflammation are at increased ... Montreal researchers. Dr. Christian A. Pineau and his team ... Centre (RI-MUHC) have linked muscular inflammation to increased cardiovascular ...
Cached Medicine News:Health News:Sometimes Angioplasty Can Wait 2Health News:Jedi Mind Medical Applications Division to Concentrate on Wheelchair Mobility Applications 2Health News:ING Awards $100,000 in Grants to Combat Childhood Obesity 2Health News:ING Awards $100,000 in Grants to Combat Childhood Obesity 3Health News:ING Awards $100,000 in Grants to Combat Childhood Obesity 4Health News:ING Awards $100,000 in Grants to Combat Childhood Obesity 5Health News:New Therapy Spares Organ in Early Esophageal Cancer 2Health News:SAGE to publish leading international headache journal Cephalalgia 2Health News:Researchers link inflammatory diseases to increased cardiovascular risk 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: